Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation

被引：62

作者：

Oikonomopoulos, Angelos ^{[1
,2
,3
]}

Kitani, Tomoya ^{[1
,2
,3
]}

Wu, Joseph C. ^{[1
,2
,3
]}

机构：

[1] Stanford Cardiovasc Inst, Stanford, CA 94305 USA

[2] Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA

[3] Stanford Univ, Sch Med, Dept Med, Div Cardiol, Stanford, CA 94305 USA

来源：

MOLECULAR THERAPY | 2018年 / 26卷 / 07期

关键词：

LONG-QT SYNDROME; HEART-FAILURE; CARDIOVASCULAR PROGENITORS; CARDIAC DIFFERENTIATION; MYOCARDIAL-INFARCTION; SELECTIVE ELIMINATION; EPIGENETIC REGULATION; SUSPENSION-CULTURE; ISCHEMIC-INJURY; SUICIDE GENE;

D O I：

10.1016/j.ymthe.2018.02.026

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Regenerative therapy has been applied to restore lost cardiac muscle and cardiac performance. Induced pluripotent stem cells (iPSCs) can provide an unlimited source of cardiomyocytes and therefore play a key role in cardiac regeneration. Despite initial encouraging results from pre-clinical studies, progress toward clinical applications has been hampered by issues such as tumorigenesis, arrhythmogenesis, immune rejection, scalability, low graft-cell survival, and poor engraftment. Here, we review recent developments in iPSC research on regenerating injured heart tissue, including novel advances in cell therapy and potential strategies to overcome current obstacles in the field.

引用

页码：1624 / 1634

页数：11

共 132 条

[1] Embryonic Stem Cell-Derived Cardiac Myocytes Are Not Ready for Human Trials [J].

Anderson, Mark E. ;

Goldhaber, Joshua ;

Houser, Steven R. ;

Puceat, Michel ;

Sussman, Mark A. .

CIRCULATION RESEARCH, 2014, 115 (03) :335-338

[2]

[Anonymous], 2015, CIRCULATION, DOI DOI 10.1161/CIR.0000000000000152

[3]

[Anonymous], 2017, CARD DIS COSTS WILL

[4]

Asimaki A., 2014, SCI TRANSL MED, V6, p240ra74

[5] Setting Up a Haplobank: Issues and Solutions [J].

Barry J. ;

Hyllner J. ;

Stacey G. ;

Taylor C.J. ;

Turner M. .

Current Stem Cell Reports, 2015, 1 (2) :110-117

[6] Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells [J].

Ben-David, Uri ;

Nudel, Neta ;

Benvenisty, Nissim .

NATURE COMMUNICATIONS, 2013, 4

[7] Selective Elimination of Human Pluripotent Stem Cells by an Oleate Synthesis Inhibitor Discovered in a High-Throughput Screen [J].

Ben-David, Uri ;

Gan, Qing-Fen ;

Golan-Lev, Tamar ;

Arora, Payal ;

Yanuka, Ofra ;

Oren, Yifat S. ;

Leikin-Frenkel, Alicia ;

Graf, Martin ;

Garippa, Ralph ;

Boehringer, Markus ;

Gromo, Gianni ;

Benvenisty, Nissim .

CELL STEM CELL, 2013, 12 (02) :167-179

[8] Evidence for Cardiomyocyte Renewal in Humans [J].

Bergmann, Olaf ;

Bhardwaj, Ratan D. ;

Bernard, Samuel ;

Zdunek, Sofia ;

Barnabe-Heider, Fanie ;

Walsh, Stuart ;

Zupicich, Joel ;

Alkass, Kanar ;

Buchholz, Bruce A. ;

Druid, Henrik ;

Jovinge, Stefan ;

Frisen, Jonas .

SCIENCE, 2009, 324 (5923) :98-102

[9] Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells [J].

Birket, Matthew J. ;

Ribeiro, Marcelo C. ;

Verkerk, Arie O. ;

Ward, Dorien ;

Leitoguinho, Ana Rita ;

den Hartogh, Sabine C. ;

Orlova, Valeria V. ;

Devalla, Harsha D. ;

Schwach, Verena ;

Bellin, Milena ;

Passier, Robert ;

Mummery, Christine L. .

NATURE BIOTECHNOLOGY, 2015, 33 (09) :970-U219

[10] The war against heart failure: the Lancet lecture [J].

Braunwald, Eugene .

LANCET, 2015, 385 (9970) :812-824

← 1 2 3 4 5 6 7 8 9 10 →